Back to results
US 10,537,637 B2Granted
Checkpoint regulator antagonists
AssigneeGensun Biopharma Inc.
InventorsJackie Z. Sheng, Bo Liu
Life of this patent
Estimating the term…
Abstract
Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-L1 are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists thereof.
Claims8
An antibody, or an antigen-binding portion thereof, comprising:
- (1) a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (HCDRs):
- HCDR1, HCDR2 and HCDR3,
- wherein HCDR1 has an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 1, 6, 11, 15, 17, 20 and 23,
- wherein HCDR2 has an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 2, 4, 7, 9, 12, 13, 16, 18, 21 and 24, and
- wherein HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 3, 5, 8, 10, 14, 19, 22 and 25 and
- (2) a light chain variable region, wherein the light chain variable region comprises three complementarity determining regions (LCDRs):
- LCDR1, LCDR2 and LCDR3,
- wherein LCDR1 has an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 26, 29, 31, 33, 35, 39, 42 and 45,
- wherein LCDR2 has an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 27, 30, 36, 37, 40, 43 and 46, and
- wherein LCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 28, 32, 34, 38, 41, 44 and 47, wherein the antibody, or the ant gen-binding portion thereof, binds specifically to human TIGIT.
13 more elements
Dependencies are inferred from the claim text.